Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.
Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.
處於發展階段的企業Alterity Therapeutics Limited宣佈通過向投資者發行期權來批准一項籌資計劃。該公告於2023年12月29日發佈，詳細說明了股東批准發行1,371,428,571份非上市短期期權和457,142,857份遠期期權，行使價分別爲0.007澳元和0.01澳元。短期期權將於2024年8月31日到期，而擬按澳大利亞證券交易所要求上市的遠期期權將於2026年8月31日到期。根據2023年12月29日股東大會批准的配售，這些期權附於已全額支付的普通股。該優惠適用於公司確定的受邀者，將於2024年1月5日結束。該公告還包括首席財務官凱瑟琳·安德魯斯的辭職以及任命菲利普·海恩斯爲新任首席財務官，自2024年1月31日起生效。
處於發展階段的企業Alterity Therapeutics Limited宣佈通過向投資者發行期權來批准一項籌資計劃。該公告於2023年12月29日發佈，詳細說明了股東批准發行1,371,428,571份非上市短期期權和457,142,857份遠期期權，行使價分別爲0.007澳元和0.01澳元。短期期權將於2024年8月31日到期，而擬按澳大利亞證券交易所要求上市的遠期期權將於2026年8月31日到期。根據2023年12月29日股東大會批准的配售，這些期權附於已全額支付的普通股。該優惠適用於公司確定的受邀者，將於2024年1月5日結束。該公告還包括首席財務官凱瑟琳·安德魯斯的辭職以及任命菲利普·海恩斯爲新任首席財務官，自2024年1月31日起生效。
有用
沒用